Final Data From the Phase 3 Alcanza Study: Brentuximab Vedotin (Bv) vs Physician's Choice (Pc) in Patients (Pts) With Cd30-Positive (Cd30+) Cutaneous T-Cell Lymphoma (Ctcl)
Hematological Oncology - United Kingdom
doi 10.1002/hon.96_2630
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley